Nonautologous multi-stressed cancer cells and uses thereof for vaccinating and treating cancers
AssigneeBrenus Pharma
InventorsBenoit PINTEUR, Paul BRAVETTI
Life of this patent
Estimating the term…
Abstract
Advanced therapy medicinal products (AMTPs) for cell therapy. In particular, a composition including stressed HT-29, HCT-116 and LoVo cells, and immunogenic stress proteins produced by these cells in response to stresses applied in vitro. The composition allows to simultaneously counteract multiple cell resistance mechanisms observed in situ in cancer cells, and is therefore suitable for vaccinating and treating cancers in human patients.
Claims20
1-17. (canceled)
A composition comprising (i) stressed HT-29, HCT-116 and LoVo cells, and (ii) immunogenic stress proteins produced by these cells in response to a stress applied in vitro.
An intermediate composition comprising (i) one of stressed HT-29 cells, stressed HCT-116 cells and stressed LoVo cells, and (ii) stress proteins,
- wherein the one of stressed HT-29 cells, stressed HCT-116 cells or stressed LoVo cells have developed resistance mechanism in response to (i) a metabolic stress, (ii) radiations and (iii) a thermal stress applied in vitro, leading to the production of the stress proteins, or
- wherein the one of stressed HT-29 cells, stressed HCT-116 cells or stressed LoVo cells have developed resistance mechanism in response to (i) a metabolic stress, and (ii) a chemical stress applied in vitro, leading to the production of the stress proteins.
Dependencies are inferred from the claim text.